Additionally, histopathological analysis of tumor tissue from one patient before and after CAR-T cell administration indicated decreased IL13Ra2 expression within the tumor, further enhancing evidence of anti-tumor activity of anti-IL13Ra2 CAR-T cells (Morgan et al. 2012). This evidence concerns the gene IL13RA2 and neoplasm.